Click here to go back to listing page
Abstract ID: 24-177
The Naïve use of Histoglob in Vernal Keratoconjunctivitis
MANMEET SINGH
Purpose
As VKC is a chronic condition, which has its exacerbations with dusty environmental conditions or may even be there throughout the year. To address this, we found the use of Histoglob, as a new safer treatment option. The main aim of this study is to determine the naïve use of Histoglob in patients of VKC and a game changer in ophthalmology
Methods
As it is a pilot study, we planned to induct 15 patients who had history of chronic VKC in this prospective, interventional pilot study. Ethical Clearance was taken from the Institutional Board for the study and informed consent was taken from parents of the wards getting enrolled in the study.
Inclusion criteria
Patient attending the Department of Cornea/Pediatric Ophthalmology, diagnosed with VKC , who were symptomatic for last 6 months
Recurrent cases of VKC or treated elsewhere for > 6months, presenting as non resolving were also included. Slit lamp bio microscopy, appropriate medical, family history and informed consent was also taken.
Patients having :
Conjunctival Hyperemia Grade 3
Papillae Grade 3 – Pappilae Size >0.3mm
Trantas Dots Grade 3- 6 dots
Superficial Punctate Keratopathy- Grade 3- Total Corneal Surface with or/and without systemic features will be included
Exclusion criteria
Symptomatic patients of less than 6 months duration
Those patients who are not willing to be a part of study
Results
As per objective assessment of the VKC score, the mean score was 7.27 +/-2.58 (Baseline/Pre-injection), 4.07 +/-1.94 (after 1st dose), 2.4+/-1.5 (2nd dose), 1.2+/-1.14 (3rd dose). On comparing, baseline i.e. week 1 the mean +/- SD was 7.267+/-2.58 has seen a fall in trendline to 3rd week mean +/- SD 1.2+/-1.14, with 95 % confidence interval with standard error 0.28 had a statistically significant p value of <0.0001. The steroid dependence had also drastically reduced from mean of 7.87 to 2.13 by the end of third week.
Conclusion
Till date no such study has been yet conducted worldwide , which makes this pilot study a unique one. A newer horizon for an additional Inj Histoglob providing active and passive immunity, thus a newer promising modality for VKC treatment.
Additional Authors
Dr Sudhakar Potti – Sankara Eye Hospital, Guntur, Andhra Pradesh, India
Dr Jasneet Kaur Sodhi – All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India